ROF2181

Overview

Información sobre este estudio

Currently, only a few international institutions use CIRT to treat pelvic bone sarcomas. Accordingly, data evaluating the potential differences in oncological outcomes, toxicities, and functional outcomes between CIRT and the more readily accessible local therapies of surgery and PT is scarce. For this reason, we propose conducting a prospective comparative effectiveness study evaluating functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

- Males and females >= 15 years of age

- Newly diagnosed, histologic confirmation of pelvic chordoma, chondrosarcoma,
osteosarcoma, Ewing sarcoma with bone involvement, rhabdomyosarcoma (RMS) with bone
involvement or non-RMS soft tissue sarcoma with bone involvement

- No evidence of distant sarcoma metastases as determined by clinical examination and
any form of imaging

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2

- Patients capable of childbearing must agree to use adequate contraception

- Ability to complete questionnaire(s) by themselves or with assistance

- Ability to provide written informed consent

- Chemotherapy per institutional guidelines is allowed

Exclusion Criteria:

- Patients receiving palliative treatment

- Recurrent disease

- Males and females < 15 years of age

- Previous radiation therapy to the site of the sarcoma or area surrounding it such that
it would be partially or completely encompassed by the radiation volume needed to
treat the current sarcoma. In other words, treatment on this study would require
re-irradiation of tissues

- Patients with distant sarcoma metastases

- Benign pelvic bone histologies

- Any of the following:

- Pregnant women

- Nursing women

- Men or women of childbearing potential who are unwilling to employ adequate contraception

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 7/27/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Ivy Petersen, M.D.

Abierto para la inscripción

Contact information:

Kayla Tottingham

(507) 293-1275

Tottingham.Kayla@mayo.edu

Jacksonville, Fla.

Investigador principal de Mayo Clinic

Bradford Hoppe, M.D., M.P.H.

Abierto para la inscripción

Contact information:

Kayla Lane M.P.H.

(904) 953-3588

Rodriguez.Kayla1@mayo.edu

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Jonathan Ashman, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publicaciones

Publications are currently not available

Información adicional de contacto

Formulario de contacto para ensayos sobre cáncer

Teléfono: 855-776-0015 (toll-free)

Preguntas de estudios clínicos para pacientes internacionales